BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Aeira Pte. Ltd. readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Aeira Pte. Ltd.'s drugs run\, fro
 m ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07106372-1335@assetmemo.bio
DTSTAMP:20261121T004115Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:stapokibart: Phase 3 readout est. (NCT07106372)
DESCRIPTION:stapokibart\, phase 3\, Atopic Dermatitis.\nStudy: A Study of S
 tapokibatrt in Children Subjects With Atopic Dermatitis\nEstimated primary
  completion: February 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/stapokibart#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07106372
URL:https://assetmemo.bio/drug/stapokibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06547333-1335@assetmemo.bio
DTSTAMP:20261121T004115Z
DTSTART;VALUE=DATE:20320429
DTEND;VALUE=DATE:20320430
SUMMARY:stapokibart: Phase 2/3 readout est. (NCT06547333)
DESCRIPTION:stapokibart\, phase 2/3\, Chronic Obstructive Pulmonary Disease
 .\nStudy: A Study of CM310 in Subjects With Moderate to Severe Chronic Obs
 tructive Pulmonary Disease\nEstimated primary completion: 29 April 2032. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/stapokibart#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06547333
URL:https://assetmemo.bio/drug/stapokibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05761028-1335@assetmemo.bio
DTSTAMP:20261121T004115Z
DTSTART;VALUE=DATE:20320531
DTEND;VALUE=DATE:20320601
SUMMARY:stapokibart: Phase 2/3 readout est. (NCT05761028)
DESCRIPTION:stapokibart\, phase 2/3\, Asthma.\nStudy: A Study of CM310 in S
 ubjects With Moderate to Severe Asthma\nEstimated primary completion: May 
 2032. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/stapokibart#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0576102
 8
URL:https://assetmemo.bio/drug/stapokibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
